

October 27, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 6, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.

The above is for your information.

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH

VINAYAK KUBER

Digitally signed by HARISH
VINAYAK KUBER
Date: 2020.10.27 21:10:19
+05'30'

Harish Kuber

Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com